Retina

Physicians use a new administration method to treat patients diagnosed with noninfectious uveitis.

A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research in Poland, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.

Nadia K. Waheed, MD, MPH, and David M. Brown, MD, provide expert advice on techniques to numb the eye before intravitreal injections.

Nadia K. Waheed, MD, MPH; and David M. Brown, MD, discuss barriers to step therapy and the impact of the COVID-19 pandemic on intravitreal injections.

Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.

The ASRS See for a Lifetime See a Retina Specialist initiative will spotlight early detection and outline the importance of seeing a retina specialist.

According to the company, pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration.

Researchers at the University of Strathclyde have developed an affordable device which takes 3D images and could shift the landscape of eye screening and treatment around the world.

Speaking at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, J. Fernando Arevalo, MD, PhD, The Edmund F. and Virginia B. Ball Professor of Ophthalmology, chairman of ophthalmology at Johns Hopkins Bayview Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, outlined his investigation of the anatomic and functional outcomes of pars plana vitrectomy, scleral buckle, or a combination of the 2, and suggested that the combination approach may need further consideration.

Speaking at the American Society of Retina Specialists 2022 annual meeting in New York, Carl Danzig, MD, detailed how treatment with faricimab in patients with neovascular AMD resulted in improvements in visual acuity, central subfield thickness and pigment epithelial detachments.

During a presentation at the American Society of Retina Specialists 2022 annual meeting in New York, Bobeck S. Modjtahedi, MD, presented results of a study that examined the accuracy of tools for predicting the risk of vision-threatening diabetic retinopathy.

In a presentation at the American Society of Retina Specialists, Dimitra Skondra, MD, PhD, points out that the low-to-moderate doses of metformin carried the greatest potential benefit in a retrospective case-control study.

In a presentation at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, Yoshihiro Yonekawa, MD, detailed that primary scleral buckling achieved the best visual acuity, and pointed out that rhegmatogenous detachments increased with age.

In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.

Nadia K. Waheed, MD, MPH; and David M. Brown, MD, review unmet needs and the importance of selecting the proper needle for intravitreal injections.

Experienced ophthalmologists provide advice for opening up high-volume intravitreal injection clinics.

Mount Sinai study is among the first to link cardiovascular risk to a specific form of age-related macular degeneration.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Charles Brodowski, MD, and Patrick Rapuano, MD, have been named co-chief residents at Wills Eye Hospital, and will lead the team of resident doctors on staff, focusing on training and recruitment while attending to their own medical resident duties.

The first in a series of upgrades to Stellaris Elite incudes maximum vacuum increase and trocar/cannula system removeable valve cap enhancement.

According to investigators, patients with age-related macular degeneration like the port delivery system for ranibizumab because it requires fewer treatments and there is less discomfort.

The 40th annual scientific meeting of the American Society of Retina Specialists will be held July 13-16 at the Jacob K. Javits Convention Center in New York.

Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.

Nadia K. Waheed, MD, MPH, and David M. Brown, MD, discuss how to accurately and safety monitor a patient post-intravitreal injection.

Expert ophthalmologists discuss the differences between in-clinic intravitreal injections and operating theaters utilizing intravitreal injections.

A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.

The FDA has accepted the supplemental Biologics License Application of aflibercept injection for review in patients with diabetic retinopathy.